Jin Matsuyama

1.6k total citations · 1 hit paper
95 papers, 1.0k citations indexed

About

Jin Matsuyama is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Jin Matsuyama has authored 95 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 53 papers in Surgery and 39 papers in Oncology. Recurrent topics in Jin Matsuyama's work include Gastric Cancer Management and Outcomes (57 papers), Metastasis and carcinoma case studies (27 papers) and Gastrointestinal Tumor Research and Treatment (23 papers). Jin Matsuyama is often cited by papers focused on Gastric Cancer Management and Outcomes (57 papers), Metastasis and carcinoma case studies (27 papers) and Gastrointestinal Tumor Research and Treatment (23 papers). Jin Matsuyama collaborates with scholars based in Japan, China and United Kingdom. Jin Matsuyama's co-authors include Yuichiro� Doki, Makoto Yamasaki, Shuji Takiguchi, Takushi Yasuda, Hiroshi Miyata, Hiroshi Imamura, Ryohei Kawabata, Kazumasa Fujitani, Masashi Fujii and Wataru Ichikawa and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Jin Matsuyama

81 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

2019 263 citations Masazumi Takahashi, Jin Matsuyama et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jin Matsuyama

Since Specialization

Citations

This map shows the geographic impact of Jin Matsuyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Matsuyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Matsuyama more than expected).

Fields of papers citing papers by Jin Matsuyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Matsuyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Matsuyama. The network helps show where Jin Matsuyama may publish in the future.

Co-authorship network of co-authors of Jin Matsuyama

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Matsuyama. A scholar is included among the top collaborators of Jin Matsuyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Matsuyama. Jin Matsuyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial 2025 ·Journal of Clinical Oncology ·Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata, Hiroki Hara, Hironaga Satake, Masazumi Takahashi, Atsushi Takeno, Hiroo Imai, Keiko Minashi, Takeshi Kawakami, Shogen Boku, Jin Matsuyama, Yasuhiro Sakamoto, Kentaro Sawada, Masato Kataoka, Hisato Kawakami, Toshio Shimokawa, Narikazu Boku, Taroh Satoh	3
2	Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial 2025 ·EClinicalMedicine ·(unknown), Yukinori Kurokawa, Yasuhiro Miyazaki, (unknown), Yoshitomo Yanagimoto, Naoki Shinno, Atsushi Takeno, Ryohei Kawabata, Yusuke Akamaru, Keijiro Sugimura, Jin Matsuyama, Yutaka Kimura, Kotaro Yamashita, Takuro Saito, Tsuyoshi Takahashi, Tomomi Yamada, Hidetoshi Eguchi, (unknown)	0
3	Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort 2024 ·Esophagus ·Tomoki Makino, (unknown), Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro� Doki	1
4	Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study 2024 ·British Journal of Cancer ·Takuro Saito, Yukinori Kurokawa, Kazumasa Fujitani, Ryohei Kawabata, Atsushi Takeno, (unknown), Shunji Endo, Jin Matsuyama, Yusuke Akamaru, Masashi Hirota, Kentaro Kishi, Shinya Urakawa, Kei Yamamoto, Koji Tanaka, Tsuyoshi Takahashi, Mikio Oka, Hisashi Wada, Hidetoshi Eguchi, Yuichiro� Doki	3
5	Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701) 2024 ·Gastric Cancer ·Yutaka Kimura, Naotoshi Sugimoto, Shunji Endo, Ryohei Kawabata, Jin Matsuyama, Atsushi Takeno, Masato Nakamura, Hiroki Takeshita, Hironaga Satake, Shigeyuki Tamura, Daisuke Sakai, Hisato Kawakami, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh	0
6	486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study 2024 ·Annals of Oncology ·Hiroyuki Takeda, (unknown), (unknown), Shigeaki Nishina, (unknown), Sho Suzuki, (unknown), Jin Matsuyama, Yoshiro Otsuki, Yusuke Akamaru, Naoki Takegawa, T Nomura, (unknown), (unknown), Yuji Negoro, (unknown), Mamoru Nakamura, (unknown), Yu Sunakawa	0
7	Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials 2023 ·Gastric Cancer ·Yutaka Kimura, Hisato Kawakami, Shigeyuki Tamura, (unknown), Jin Matsuyama, Hiroshi Imamura, Shöhei Iijima, Daisuke Sakai, Yukinori Kurokawa, (unknown), Toshimasa Tsujinaka, (unknown), Taroh Satoh	1
8	Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer 2022 ·Medicine ·(unknown), Terumasa Yamada, Masami Ueda, (unknown), Shinsuke Nakashima, Katsuya Ohta, (unknown), Jin Matsuyama, Masakazu Ikenaga, (unknown)	3
9	Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial 2021 ·Gastric Cancer ·Yasuhiro Miyazaki, Takeshi Omori, Kazumasa Fujitani, Junya Fujita, Ryohei Kawabata, Hiroshi Imamura, Kazuyuki Okada, (unknown), Motohiro Hirao, Jin Matsuyama, Takuro Saito, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro� Doki	38
10	Bridge to surgery using a self-expandable metallic stent for stages II–III obstructive colorectal cancer 2020 ·BMC Surgery ·Katsuya Ohta, Masakazu Ikenaga, Masami Ueda, (unknown), (unknown), Shinsuke Nakashima, Takashi Nojiri, Jin Matsuyama, Shunji Endo, (unknown), Ichizo Kobayashi, Masahiko Tsujii, Terumasa Yamada	3
11	Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer 2020 ·Cancer Reports ·(unknown), Terumasa Yamada, Ryo Kato, Masami Ueda, (unknown), Shinsuke Nakashima, Katsuya Ohta, Jin Matsuyama, Masakazu Ikenaga, (unknown)	5
12	Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials 2020 ·International Journal of Clinical Oncology ·Hisato Kawakami, Kazumasa Fujitani, Jin Matsuyama, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, (unknown), Takao Tamura, Naotoshi Sugimoto, Daisuke Sakai, Toshimasa Tsujinaka, Masahiro Goto, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh, (unknown)	5
13	Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancer 2019 ·Cancer Reports ·(unknown), Terumasa Yamada, Ryo Kato, Masami Ueda, (unknown), Shinsuke Nakashima, Katsuya Ohta, Jin Matsuyama, Masakazu Ikenaga, (unknown)	6
14	Prognostic factors for cytology-positive gastric cancer 2018 ·Surgery Today ·Shunji Endo, Masakazu Ikenaga, Katsuya Ohta, Masami Ueda, (unknown), Ryo Kato, (unknown), Jin Matsuyama, Kazuhiro Nishikawa, Terumasa Yamada	14
15	Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial 2016 ·Annals of Surgical Oncology ·Hiroshi Imamura, Kazuhiro Nishikawa, Kentaro Kishi, Kentaro Inoue, Jin Matsuyama, Yusuke Akamaru, Yutaka Kimura, Shigeyuki Tamura, Ryohei Kawabata, Junji Kawada, Yoshiyuki Fujiwara, (unknown), (unknown), Mari Takagi, Atsushi Takeno, Toshio Shimokawa	68
16	A case of axial torsion of big Meckel's diverticulum 2012 ·Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) ·Masayuki Hiraki, Jin Matsuyama, Kazuhiko Hashimoto, (unknown), (unknown)	1
17	p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus 2009 ·Annals of Surgical Oncology ·Makoto Yamasaki, Hiroshi Miyata, Yoshiyuki Fujiwara, Shuji Takiguchi, Kiyokazu Nakajima, Toshirou Nishida, Takushi Yasuda, Jin Matsuyama, Masaki Mori, Yuichiro� Doki	43
18	Evaluation of clinical significance of¹⁸F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus 2007 ·Diseases of the Esophagus ·Hiroshi Miyata, Y. Doki, Takushi Yasuda, Makoto Yamasaki, (unknown), Yoichi Makari, Jin Matsuyama, Takafumi Hirao, Shuji Takiguchi, Yasuhiro Fujiwara, Morito Monden	23
19	A Case of Aberrant Pancreas Cancer in the Jejunum. 2001 ·The Japanese Journal of Gastroenterological Surgery ·(unknown), Kenji Kobayashi, Koji Yoshida, Yosuke Seki, Jin Matsuyama, Taro Aoki, (unknown), Keisuke Miyauchi, Tadashi Kaneko	4
20	Two Cases Survived For Long-Term After Resection Of Colon Metastasis Of Gastric Cancer. 2001 ·The Japanese Journal of Gastroenterological Surgery ·(unknown), Shigeyuki Tamura, Jin Matsuyama, (unknown), Keisuke Miyauchi, (unknown), Kouji Yoshida, (unknown), (unknown), Tadashi Kaneko	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact